M
Masakazu Toi
Researcher at Kyoto University
Publications - 658
Citations - 28522
Masakazu Toi is an academic researcher from Kyoto University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 69, co-authored 578 publications receiving 23200 citations. Previous affiliations of Masakazu Toi include The Breast Cancer Research Foundation & Tokyo Metropolitan Komagome Hospital.
Papers
More filters
Journal ArticleDOI
Increased estrogen sulfatase (STS) and 17β-hydroxysteroid dehydrogenase type 1(17β-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients
Niramol Chanplakorn,Niramol Chanplakorn,Pongsthorn Chanplakorn,Pongsthorn Chanplakorn,Takashi Suzuki,Katsuhiko Ono,Monica S.M. Chan,Yasuhiro Miki,Shigetoyo Saji,Takayuki Ueno,Masakazu Toi,Hironobu Sasano +11 more
TL;DR: Significant alterations of intratumoral enzymes, especially 17β-HSD1 and STS, were correlated with Ki67 reduction after neoadjuvant EXE therapy and may represent the compensatory response of breast carcinoma tissues to estrogen depletion.
Journal ArticleDOI
Plasma Nucleosome Levels in Node-Negative Breast Cancer Patients.
TL;DR: Increased PNLs were found in breast cancer patients, andPNLs seem promising as a new prognostic factor for both node-negative and node-positive breast cancer.
Journal ArticleDOI
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Peter A. Kaufman,Masakazu Toi,Patrick Neven,Joohyuk Sohn,EM Grischke,Valerie Andre,Clemens Stoffregen,Sarah Shekarriz,Gregory L Price,Gebra Cuyun Carter,George W. Sledge +10 more
TL;DR: Results support treatment with abemaciclib plus fulvestrant in a population of patients with endocrine-resistant HR+, HER2-negative ABC and impact on health-related quality of life (HRQoL) is important to consider, given the palliative nature of ABC treatment.
Journal ArticleDOI
Radicol, a microbial cell differentiation modulator, inhibits in vivo angiogenesis
Tsutomu Oikawa,Hideki Ito,Hiromi Ashino,Masakazu Toi,Takeshi Tominaga,Ikuo Morita,Sei-itsu Murota +6 more
TL;DR: Results indicate that radicicol might be a potential drug for treating different angiogenesis-dependent diseases, such as solid tumors, psoriasis, rheumatoid arthritis, and diabetic retinopathy.
Journal ArticleDOI
Anti-Tumor Activity and Immunotherapeutic Potential of a Bisphosphonate Prodrug.
Yoshimasa Tanaka,Yoshimasa Tanaka,Masashi Iwasaki,Kaoru Murata-Hirai,Kenji Matsumoto,Kosuke Hayashi,Haruki Okamura,Tomoharu Sugie,Nagahiro Minato,Craig T. Morita,Masakazu Toi +10 more
TL;DR: In this paper, the authors synthesize bisphosphonate prodrugs and found that they efficiently limit tumor cell growth, and that they could enhance the effectiveness of adoptive cancer immunotherapy with γδ T cells.